Nalaganje...

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Med
Main Authors: Iacoboni, Gloria, Villacampa, Guillermo, Martinez‐Cibrian, Nuria, Bailén, Rebeca, Lopez Corral, Lucia, Sanchez, Jose M., Guerreiro, Manuel, Caballero, Ana Carolina, Mussetti, Alberto, Sancho, Juan‐Manuel, Hernani, Rafael, Abrisqueta, Pau, Solano, Carlos, Sureda, Anna, Briones, Javier, Martin Garcia‐Sancho, Alejandro, Kwon, Mi, Reguera‐Ortega, Juan Luis, Barba, Pere
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2021
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124109/
https://ncbi.nlm.nih.gov/pubmed/33932100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3881
Oznake: Označite
Brez oznak, prvi označite!